UNSPSC 51343601: Citenazone

This classification denotes an antiviral agent with the molecular formula C7H6N4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34RU0N173Q, chemically known as 2-thiophenecarbonitrile, 5-formyl-, thiosemicarbazone but generally known as citenazone, which bears US NIH Compound Identifier 3033956. European Medicines Agency schedules Citenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07488MIG.

UNSPSC 51343601 Citenazone, a Commodity code, does not align with the recent state and local opportunities tagged under it. The code nominally refers to a specific pharmaceutical active ingredient, yet the four recent solicitations—covering naloxone procurement, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals distributed through cooperative purchasing—span naloxone dispensing systems, pharmacy benefit management, emergency medical supplies, and bulk pharmaceutical contracting. None explicitly solicits citenazone. The mismatch suggests either a tagging error in the source data or that state and local procurement offices are using the code as a placeholder for broader pharmaceutical acquisition rather than a targeted single-ingredient buy.

The recent activity involves a mix of issuing bodies: a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), a municipal fire department (City of Tampa), and a multi-state cooperative purchasing alliance (Minnesota MMCAP, covering state and participating local governments including Oregon). Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the City of Tampa's invitation to bid for 169 line items of medical and first aid supplies for the Fire Department Rescue Division (estimated contract value $700,000.00, sheltered as a small local business enterprise set-aside with a 5 percent bid discount up to $10,000, response due March 13, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, proposals due March 26, 2026. Activity clusters in Florida, Texas, and the upper Midwest. Given the code-to-opportunity misalignment, the code shows little relevant recent activity for pharmaceutical-specific procurement professionals.